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Abstract
The integrated analysis of genotypic and expression data for association with complex traits could identify novel genetic
pathways involved in complex traits. We profiled 19,573 expression probes in Epstein-Barr virus-transformed
lymphoblastoid cell lines (LCLs) from 299 twins and correlated these with 44 quantitative traits (QTs). For 939 expressed
probes correlating with more than one QT, we investigated the presence of eQTL associations in three datasets of 57 CEU
HapMap founders and 86 unrelated twins. Genome-wide association analysis of these probes with 2.2 m SNPs revealed 131
potential eQTLs (1,989 eQTL SNPs) overlapping between the HapMap datasets, five of which were in cis (58 eQTL SNPs). We
then tested 535 SNPs tagging the eQTL SNPs, for association with the relevant QT in 2,905 twins. We identified nine
potential SNP-QT associations (P,0.01) but none significantly replicated in five large consortia of 1,097–16,129 subjects. We
also failed to replicate previous reported eQTL associations with body mass index, plasma low-density lipoprotein
cholesterol, high-density lipoprotein cholesterol and triglycerides levels derived from lymphocytes, adipose and liver tissue.
Our results and additional power calculations suggest that proponents may have been overoptimistic in the power of LCLs
in eQTL approaches to elucidate regulatory genetic effects on complex traits using the small datasets generated to date.
Nevertheless, larger tissue-specific expression data sets relevant to specific traits are becoming available, and should enable
the adoption of similar integrated analyses in the near future.
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Introduction
The availability of high throughput and low cost genotyping
technologies have lead to recent successes of genome-wide
association (GWA) studies in mapping genes contributing to
various complex traits including diabetes, lipids and bone mineral
density (BMD) and obesity [1–3]. Many consistently replicated
associations between clinical phenotypes and genetic variants have
been found to date. However, most of these studies – particularly
those involving quantitative traits (QTs) - require very large
sample sizes to detect modest effects which explaining only a small
fraction of the heritability associated with these traits; furthermore,
they do not provide experimental data supporting the functional
and regulatory consequences of the associations [4]. Linkage
disequilibrium (LD) across the associated region and time-
consuming experiments to gain functional evidence make
identification of the causal variants difficult. A common approach
employed by various studies to gain insight into the possible
regulatory role of replicated disease-associated Single Nucleotide
Polymorphisms (SNPs) is to investigate their correlation with
transcript levels. For instance, Moffatt et al. (2007) found that the
most significant SNPs associated with childhood asthma risk in a
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e22070large LD region with 19 candidate genes accounted for 29.5% of
the variance of ORMDL3 transcript levels measured in lympho-
blastoid cell lines (LCLs) and thus ORMDL3 was prioritized as a
primary biological candidate for the asthma locus [5]. In a similar
approach, a SNP near TNFRSF11B, strongly associated with BMD
was found to be associated with a 50% decrease in expression
levels of TNFRSF11B in LCLs, providing a putative mechanism
for the SNP-trait association [2].
These approaches still rely, however, on the detection of
replicated SNP-disease associations in the first instance. Several
recent studies of the genetic basis of regulatory variation
(expression Quantitative Trait Loci (eQTL) studies) have shown
that cis-acting genetic variants can be strongly associated with gene
expression levels generated from various human samples including
LCLs [6–11], whole blood [12], fresh lymphocytes [13],
abdominal fat [12] and liver tissue [14], and some of these cis-
acting variants were reported to be correlated with a few clinical
QTs [2,5,12–16]. The general question remains, however, to what
extent gene expression traits that are likely to be under stronger
genetic influence than ‘downstream’ complex traits [13,17], can
help in uncovering novel genetic pathways involved in phenotypic
variation. An additional question is whether LCLs, used
extensively to date in eQTL discovery studies [6–11] are suited
to elucidating clinically relevant expression patterns.
In humans, LCLs have been commonly used in eQTL studies
[6–11], mainly because they are an easily accessible source of a
single cell type, in which immediate environmental influences and
variation manifested by other cell types on expression are
minimized compared to ex vivo samples thus decreasing noise
and allowing - in theory - a more powerful investigation of genetic
influences. However, LCLs -being removed from immediate
environmental influences such as inflammatory responses –are
transformed and cultured under artificial conditions and may not
represent the natural gene expression state in vivo. In addition, the
large percentage of pauciclonality in LCLs combined with
widespread monoallelic expression has been shown to lead to
highly differential expression profiles between LCLs and ex vivo
cells [18,19]. These differences between cell lines and natural
tissues might significantly reduce effect sizes of both QT/disease-
gene expression and eQTL associations. As long as LCLs mirror
the relevant patterns of regulation, an integrated analysis of
replicated eQTLs with clinical phenotypes could provide a more
powerful and informative approach to elucidate the genetic
regulation of complex traits.
Such integrated analyses - ideally involving evidence from
multiple datasets - are, however, methodologically not straight-
forward. Potential problems include the unknown relevance of
LCL expression profiles for the phenotype in question. Indeed
comprehensive collections of more relevant human tissues are not
commonly available for many clinical phenotypes. Moreover,
several studies have highlighted cell type- or tissue specific genetic
effects, where others found that a substantial numbers of eQTLs
are shared across tissues [12,20]. A few studies compared the
overlap of eQTLs found in LCLs and primary tissues and found
that a large number of eQTLs detected in LCLs can also be
detected in primary tissues [21–23].
In addition, differences in probe annotation and SNP tag
coverage across datasets may hamper comparisons across studies.
Gene expression profiles obtained from different platforms in
different laboratories analysed with the same annotation and
statistical methods [24–26] may improve the reproducibility of
eQTL studies [19,25,27].
In this study, we investigated the potential of combining gene
expression data from LCLs and genotype data to uncover
associations with a more regulatory and functional role between
clinical traits and underlying genetic variants. Specifically, rather
than focussing solely on the direct association between genetic
variants and a single clinical trait, or between genetic variants and
expression phenotypes, we sought to determine whether an
integrated approach would enable the detection of clinically
relevant associations. For this purpose, we used clinical, LCL
expression, and genotyping data from the UK Adult Twin registry,
a longitudinal epidemiological study of 11,000 twins (mostly
female) for whom extensive clinical, anthropometric, life-style, and
demographic information, as well as a wide range of biological
measurements have been collected [28]. In addition, we aimed to
detect robust eQTLs by using the twin data as well as three sources
of publicly available HapMap LCL expression data generated on
Illumina platforms but re-analysed using identical methodology
since they used different array versions and were produced in
different laboratories. Although the size of the datasets employed
for eQTL detection were only likely to enable the detection of cis
eQTLs relevant to QTs - the focus of our study - we also present
relevant results for trans effects. Our study is the first to investigate
the utility of eQTLs in a large number of QTs (N=44), which
include BMD, anthropometric, metabolic and fat-related traits.
Results
The study design comprised four analysis stages (Figure 1): I)
prioritisation of clinically relevant expression probes through
correlation of 44 QTs with gene expression in LCLs of 299 female
twins; II) identification of SNPs associated with QT-correlated
expression probes (eQTLs) in 57 CEU HapMap individuals and
86 unrelated twins; III) confirmation of QT-SNP association in the
larger cohort of 2,905 female twins; IV) replication of QT-SNP
association in large, independent cohorts. The hypothesis behind
this design was that focussing eQTL SNP detection on expression
traits correlated with QTs should enrich for QT-SNP associations.
This screening step could increase power of detection not only
because expression traits are likely to be under stronger genetic
control than more downstream QTs, but also because it
potentially reduces the extent of multiple testing otherwise
inherent to genome-wide QT association approaches.
We selected 44 QTs measured in the twin cohort including
anthropometric traits, BMD, fat-related traits, electrolytes, liver
function markers, bone markers, lipids and glycemic traits
(Methods, Text S1). We first estimated the heritabilities of these
QTs in the entire twin cohort of 6,533 female twins (Figure 2A). In
general, the lowest heritabilities were found for electrolyte
measurements (h
2: 0.15–0.37) and highest heritabilities were
found for fat-related (h
2: 0.43–0.82) and BMD traits (h
2: 0.62–
0.79). To investigate the correlation structure of the 44 QTs,
principal components analysis (PCA) on the 44 QTs was
performed discriminating three clusters: 9/12 fat-related traits,
four BMD traits and four blood pressure traits (Figure 2B,
Figure S1).
Stage I: Correlations between QTs and gene expression
levels in female twins
In Stage I, we generated gene expression profiles for a subset of
299 female Caucasian twins with available LCLs using Illumina
Human WG-6 V2 Sentrix BeadArrays containing 46,713 probes.
A total of 19,573 (42%) expression probes (11,854 Ensembl genes)
were detected in at least 10% of the individuals (Figure 1) and had
no SNPs in their sequence. We tested these expression probes for
association with each of the QTs using linear mixed models,
adjusting for the confounding effect of RNA Integrity Number,
Quantitative Trait-eQTL Associations from LCLs
PLoS ONE | www.plosone.org 2 July 2011 | Volume 6 | Issue 7 | e22070cell culture duration, age, and for correlation of measurements due
to experimental design (see Methods). Given its potential
confounding effect, we investigated the effect of smoking on gene
expression measurements, but found that only one expression
probe-QT correlation was mediated by smoking (Text S1, Table
S1). In total, 939 expression probes (4.8%) correlated with at least
one QT at a nominal significance value of p,10
23, and 137
(0.7%) at p,10
24 (Table 1). Of the 939 expression probes, 160
correlated with 2–8 QTs at p,10
23, giving a total of 1,176
expression probe-QTs correlations (Table S2). The five expression
probes correlated with $5 QTs were correlated with blood
pressure and fat-related traits. The 939 expression probes
Figure 1. The study design comprises four different analysing stages. Stage I: Correlation analysis between 44 QTs and 19,573 detected
gene expression levels in 299 female twins profiled in LCLs. Stage II: eQTL detection of nominally significant QT-correlated probes in 57 CEU HapMap
individuals and 86 unrelated twins. Stage III: confirmation of QT-SNP association in 2,905 female twins. Stage IV: Replication of QT-SNP associationi n
large, independent cohorts.
doi:10.1371/journal.pone.0022070.g001
Quantitative Trait-eQTL Associations from LCLs
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23 were taken to Stage II.
Assuming independence between the QTs, the estimated false
discovery rate (FDR) was 0.73 across the 19,573 probes and 44
QTs. Given the correlations between many of the QTs, this
estimate was likely to be a substantial overestimate. At this stage,
however, we did not adjust for multiple testing because: i) results of
Stage I were taken forward to the subsequent confirmation Stages
II–IV during which appropriate correction was made; and ii)
substantial correlations exist between QTs (Figure S1) and
between expression probes and such adjustments would be
extremely stringent.
Stage II: eQTL analysis in the HapMap and Twin datasets
To uncover consistent eQTL signals underlying expression
signals correlated with QTs, we analysed and annotated three
LCL expression datasets from 57 CEU HapMap founders
(Wellcome Trust Centre for Human Genetics (WTCHG) version
1 (V1), WTCHG version 2 (V2), Sanger V1 [11]) that were
measured on two Illumina Beadchips (V1 and V2) in two
laboratories using the same methods (Text S1, Table S3 and
S4). In addition, we conducted eQTL detection in 86 unrelated
twins from Stage I (Twin V2) for which we had genotypes and
LCL expression data available. High reproducibility among the
same HapMap individuals was observed for 184 identical probes
that were detected in at least 10% of individuals in both WTCHG
V1 and WTCHG V2 datasets (spearman r=0.96 (standard
deviation=0.015)). Although our main focus - given the size of the
datasets - was on detecting cis eQTLs, we also included trans signals
for the purpose of contrast and completeness. Associations in cis
were defined as SNP-probe associations where SNPs were located
within a region 1 Mb upstream or downstream of the expression
probe midpoint. We considered all other associations as
associations in trans [11]. The rationale for the 1 Mb window
was that most of the eQTLs lie either within genes or close to the
gene [7,17,29].
For the eQTL analyses, we selected 718 of the 939 expression
probes (640 Ensembl genes) from Stage I that were detected in at
least 10% of the HapMap individuals (WTCHG V2) and had well-
mapped autosomal locations on NCBI build 36 (Figure 1). Our
primary aim was to leverage the combined evidence of eQTL
detection across the different datasets, with overlap in signals
between SNP-expression probe pairs from the HapMap datasets
providing evidence of technical replication, and overlap between
SNP-expression probe pairs from HapMap and the twin dataset
providing evidence of biological replication. However, overlap
analyses could involve only those 546/718 (76%) of the V2 probes
(594 Ensembl genes) which had the same Ensembl transcript
target as at least one probe on the Illumina V1 Beadchip.
We tested the 546 probes (corresponding to 1,050 V1
expression probes) for eQTL association in the three HapMap
datasets using a nominal significance threshold of p,10
23 in all
three datasets (‘overlap’ analysis). To capture the increased
coverage of RefSeq genes on the V2 Beadchips compared to V1
Beadchips, we also conducted eQTL analyses using the WTCHG
V2 and Twin V2 datasets only for all prioritised 718 V2 probes.
For the WTCHG V2 and Twin V2 analyses, we applied a
nominal significance threshold of p,5
*10
27, a threshold applied
in GWA studies of a single trait [3]. We fitted additive models
between normalised expression values of each of the selected
expression probes and 2.2 million SNPs downloaded from www.
HapMap.org [30] in the HapMap datasets and 296,308 SNPs in
Twin V2 (see Methods). We tested additive models only as a
previous study showed that dominance had a minimal effect on
gene transcription [7].
After removal of eQTLs with different directional effects, the
overlap analysis yielded 131 expression probes (135 Ensembl
genes) associated with at least one SNP at p,10
23 in all three
HapMap datasets (1,989 eQTL SNPs). Five of the expression
probes (five Ensembl genes) provided 58 cis eQTL associations
(Table 2). The remaining 129 expression probes (133 Ensembl
genes) resulted in 1,959 trans eQTL associations. In the WTCHG
V2 dataset, we identified 297 probes (251 Ensembl genes) with a
total of 1,954 eQTL associations (p,5
*10
27, 1,932 eQTL SNPs);
five of the 297 probes (four Ensembl genes) had 39 eQTL
associations in cis (Table 2).
In the Twin V2 dataset, 131 probes (110 Ensembl genes) with
252 eQTL associations (242 eQTL SNPs) were found; ten of the
131 probes (10 Ensembl genes) provided 42 eQTL associations in
cis. The corresponding FDR for cis eQTL analysis of 718 probes in
the WTCHG V2 analysis and Twin V2 at a pvalue of 5*10
27 was
0.01 and 0.001, respectively.
Only four eQTL associations from the overlap analysis (two
probes, two Ensembl genes) and 229 eQTL associations (164
probes, 142 Ensembl genes) from the WTCHG V2 were
Table 1. Number of correlations between 44 QTs and 19,573 expression probes (11,854 Ensembl genes) at different significance
levels for 299 female twins.
P value threshold No. of QTs (N=44)
No. of correlated probes
(N=19,573) No Ensembl genes No. of probe-QT correlations
,10
23 44 939 703 1,176
,10
24 34 137 91 161
,10
25 12 15 12 18
,10
26 33 33
doi:10.1371/journal.pone.0022070.t001
Figure 2. Heritability estimates and PCA of QTs. A) Heritability estimates with 95% confidence intervals of 44 QTs ordered by clinical
subgroups. Abbreviations are: bp1=first blood pressure measurement; bp2=second blood pressure measurement; alb cor calcium=albumin
corrected calcium; ggt=gamma-glutamyl transpeptidase; bmi=body mass index; circumf=circumference; tot.fat.mass%=total fat mass (%);
bmd=bone mineral density; alkalinephosph=alkalinephosphatase; crp=C-reactive protein; hdl=high-density protein cholesterol; ldl=low-density
protein cholesterol B) PCA of 44 QTs. Three clusters of QTs were discriminated: fat related QTs including weight, BMI, total fat mass (g), total fat mass
(%), central fat (g), central fat (%), hip circumference, waist circumference and leptin, BMD QTs including forearm, hip, femoral neck and spine BMD
and a cluster with four blood pressure QTs.
doi:10.1371/journal.pone.0022070.g002
Quantitative Trait-eQTL Associations from LCLs
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23 threshold. Fifteen
of the 164 probes (13 Ensembl genes) provided 39 eQTL
associations in cis. Combining the WTCHG V2 and Twin V2
datasets, we tested these 229 eQTL associations in a fixed-effects
meta-analysis [31]. After checking for heterogeneity, these analyses
resulted in 102 eQTL associations (85 probes, 73 Ensembl genes)
at the 5*10
27 threshold of which nine probes (seven Ensembl
genes) showed 18 eQTL associations in cis.
To investigate whether the reduced sets of expression probes
resulting from Stages I and II are more likely to be functionally
related to the QTs, we summarised them in ‘‘Biological Process’’
Gene Ontology (GO) categories using DAVID [32] and assessed
heritability distributions (see Methods). The 546 expression probes
from Stage I showed an enrichment of common GO terms such as
‘‘cell fate specification’’ (p=4.5*10
24, FDR P=0.24) whereas the
131 probes identified from the overlap analysis (Stage II) and the
85 probes identified from the meta-analysis showed an excess of
the GO term ‘cellular lipid metabolism’ (GO:00044255,
p=2.0*10
23, FDR P=0.11) and ‘negative regulation of response
to stimulus’(GO:0048585, p=4.0*10
24, FDR P=0.10) compared
to the 18,838 detected probes, respectively.
Despite the small sample size, the frequency of expression
probes with heritabilities .0.2 increased throughout the selection
strategy, from 15% of all 19,573 detected probes, 20% of the 718
QT-correlated probes, 21% of the 546 the QT correlated probes
annotated to WTCHG V1 probes, 23% of the 297 eQTL probes
identified from WTCHG V2 dataset, 27% of the 131 eQTL
probes from Twin V2 dataset, to 31% of 131 eQTL probes from
the overlap analysis and 31% of 85 eQTL probes from the meta-
analysis (Figure 3). The increasing percentage of heritable probes
and the enrichment of GO terms suggested that our filtering
strategy up to Stage II was successful in increasing the proportion
of true-positive relative to false-positive QT-related signals.
Stage III: Confirmation of associations between eQTL
SNPs and QTs in twin cohort
In Stage III, nominally significant eQTL SNPs and those in LD
(r
2.0.8) were tested for association with the QTs with which the
relevant expression probes were previously correlated (Stage I), in
the larger cohort of 2,905 female twins (Figure 1). For these twins
whole genome genotyping was available from the twin cohort
employing 296,308 SNPs with the Illumina HumanHap 300 k
Duo Beadchip (Illumina, San Diego, USA) after appropriate
quality checks (see Methods). eQTL and GWA signals were
considered overlapping for SNPs on the GWA chip that were in
LD with the eQTL SNP. For the overlap analysis, 535 SNPs on
the GWA chip were in LD (r
2.0.8) with 1,482/1,989 eQTL SNPs
(75%) from Stage II (see Methods). In the WTCHG V2 analysis,
451 SNPs were in LD (r
2.0.8) with 1,357/1,932 (70%) eQTL
SNPs (Table S5). The percentage of tagged eQTL SNPs in the
overlap analysis was greater than for the WTCHG V2 analysis,
possibly explained by the increased percentage of rarer eQTL
SNPs in the WTCHG V2 analysis: 54% of untagged SNPs had a
minor allele frequency (MAF) #0.1 compared to 33% in the
overlap analysis (Figure S2).
We examined the association between 535 SNPs from the
overlap analysis with 37 QTs (corresponding to 141 probe-QT
correlations and 1,498 eQTL associations), 451 SNPs from
WTCHG V2 analysis with 41 QTs (268 probe-QT correlations
and 1,370 eQTL associations), 242 SNPs with 38 QTs from Twin
V2 (161 probe-QT correlations and 252 eQTL associations) and
101 SNPs with 36 QTs from the meta-analysis (105 probe-QT
correlations and 102 eQTL associations). After removal of
associations with inaccurate annotations or outliers in gene
expression, we found 15 non-overlapping loci associated with 10
different QTs with a p-value,0.01 (Table 3). For these 16 SNP-
QT associations with p,0.01, eQTL associations were tested in
the full set of 86 twin families (161 individuals) to obtain a more
precise estimate of significance (Table 3). For 8/15 of the
associations, the constituting eQTL evidence was based on the
overlap analysis (+/2 Twin V2), whereas 5/15 associations had
eQTL evidence from WTCHG V2 or Twin V2 only. Three
associations showed eQTL evidence from the meta-analysis (one
association was overlapping with the overlap analysis).
Only one of the QTs, phosphate, appeared to have contributing
cis eQTL associations, for rs10511409 and rs7647266 (r
2=0.25) on
expression probe ILMN_27140, with supporting evidence from all
HapMap datasets and the Twin V2 dataset or the meta-analysis,
respectively. However, although ILMN_27140 had been selected
because of its nominal correlation with phosphate levels in the 299
twins, the association between these SNPs and phosphate levels in
2,905 twins was non-significant after FDR correction (p.0.11).
All other QT-associated eQTL results were in trans, with
marginal evidence for rs17596670 or rs313289 (r
2=0.89) and
ILMN_19002 (chloride concentration), and rs716618 and
ILMN_552 (height). However, none of the corresponding QT-
SNP associations were significant in the larger cohort of 2,905
twins after FDR correction [33]. Only the trans association from
Table 2. Number of probes with eQTL SNPs derived from GWA analysis of 546 (overlap analysis) and 718 (WTCHG V2) expression
probes in 57 HapMap founders and 86 unrelated twins.
Dataset
eQTL p value
threshold
No. mapped
probes with eQTL
a
No. Ensembl
genes No. eQTLs
No
SNPs
No. probes with
cis eQTL SNPs
No. cis
eQTLs
b
Overlap eQTL analysis
WTCHG V2/WTCHG V1/Sanger V1 ,10
23 131 135 2,017 1,989 5 58
Dataset-specific eQTL analysis
WTCHG V2 ,5*10
27 297 251 1,954 1,932 5 39
Twin V2 ,5*10
27 131 110 252 242 10 42
Meta-eQTL analysis
WTCHG V2+Twin V2 ,5*10
27 85 73 102 101 9 18
aProbes annotated to genomic location in build 36.
bcis eQTL were defined as an SNP-probe association where the distance from probe genomic midpoint to SNP genomic location was less than or equal to 1 Mb; all other
eQTLs were defined as trans eQTLs.
doi:10.1371/journal.pone.0022070.t002
Quantitative Trait-eQTL Associations from LCLs
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(FDR adjusted p=0.03).
Stage IV: Follow-up of SNP-QT associations in
independent cohorts
We were able to test 9/16 QT-SNP associations (five QTs) for
replication in five large-scale consortia datasets (Figure 1; Table 3):
three GWAs from Soranzo et al. (2009) (height, N=5,828);
Genmets (C-reactive protein (crp), N=1,097) [34]; ENGAGE
(triglycerides, N=16,129) [35]; GlobalBP (diastolic blood pres-
sure, N=26,644) [36]; and KORA (phosphate, N=1,756) [37].
We were unable to identify suitably large replication cohorts for
hip circumference, serum chloride and potassium, hip and femoral
neck BMD. None of the cohorts had gene expression data
available to replicate the gene-expression-QT correlation.
The cis associations between rs10511409 and rs7647266 and
ILMN_27140 had been selected because of its nominal correlation
with phosphate levels in the 299 twins. Subsequent analyses in an
independent dataset of 1,756 individuals (KORA) did not provide
evidence that these SNPs were associated with phosphate levels
(p.0.09). Of the associations between QTs and SNPs which
showed consistent trans eQTL evidence (for diastolic blood
pressure, triglycerides, crp and height), only one association,
between height and rs1482455 (tagging eQTL SNP rs716618 with
r
2=0.84) reached borderline significance (p=0.01) in a meta-
analysis of 5,828 females. However, this result was not significant
after applying a Bonferroni correction allowing for the nine
independent tests conducted (p,0.006).
Investigation of published eQTL-QT associations
Several significant cis eQTL-QT associations have been
published for QTs also included in our study, including
associations with body mass index (BMI), plasma low-density
lipoprotein cholesterol (LDL), high-density lipoprotein cholesterol
(HDL) and triglycerides (Table S6) [12–14,38]. Although none of
these findings were derived from LCLs (fresh lymphocytes, liver or
adipose tissue were used), we set out to investigate whether the
associations could be detected in our datasets. Of the relevant 29
expression probes (25 genes) only 19 were expressed in the LCL
dataset of 299 twins. None of the QT-expression probe
correlations in the LCLs from the 299 female twins were
nominally significant (p,10
23). Suggestive evidence was found
for the correlations between the expression probes targeting
FADS1 and FADS3 and HDL (p=4*10
23) but eQTL analysis in
the three HapMap or Twin V2 datasets did not confirm the
reported significant cis eQTL associations.
Power and sample size issues and potential limitations
In any association study, power and sample size of the study
design need careful consideration prior to analysis. Given the
m u l t i - s t a g ed e s i g ni no u rs t u d y ,t h ec o m p l e xc o r r e l a t i o n
structure between QTs and between expression probes, the
unknown effect sizes of QT-expression trait correlations (Stage
I) and eQTLs (Stage II), the tagging of eQTL SNPs (Stage III)
and the availability of suitable replication cohorts (Stage IV),
simulation-based power calculations were unfeasible. Instead -
given that an important aim of the study was to examine the
utility of LCL-derived eQTL signals in relation to complex
trait analysis - we adopted a much simplified scenario and
calculated the likely power and sample sizes needed for cis
eQTL detection. We estimated sample sizes required for a
single expression trait in a GWA using single-SNP type I error
rates of 5*10
27 and 1.0*10
23 with 80% and 50% power
(Figure 4) [39].
Figure 3. Density plot of heritability estimates of gene expression probes for different analysis stages.
doi:10.1371/journal.pone.0022070.g003
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needed to reliably detect effect sizes that explain a small
proportion of the QTL variance (in additive models) of the
expression trait at 5*10
27 or even 1.0*10
23 significance thresholds
with .80% power (Figure 4). For the cis eQTLs found in Stage II,
a large portion of the QTL variance appeared to be explained by
the association ranging between 18%–51% in the overlap analysis,
37%–59% in the WTCHG V2 analysis and 27%–77% in the
Twin V2 analysis.
Discussion
Many GWAs have been conducted to find genetic variants
underlying complex traits. A number of eQTL studies have
identified genetic variants underlying gene expression mostly in
LCLs. A few studies in humans have adopted an integrated
approach using datasets in which genotypes and gene expression
profiles – from adipose and liver tissue or lymphocytes – were
correlated with a clinical trait [12–14]. Here, we investigated the
potential of integrating gene expression data from LCLs and
genotype data for a large number of clinical QTs (N=44). Our
multistage study, which incorporated eQTL signals from three
sources of publicly available LCL expression data from 57
HapMap founders as well as an independent dataset of 161 twins,
did not result in the identification of robust eQTL associations
relevant to the 44 QTs. Using LCLs, we also failed to replicate
previous reported eQTL associations with BMI, LDL, HDL and
triglycerides levels derived from fresh lymphocytes, adipose and
liver tissue [12–14,38]. Additional power calculations suggested
that integrated approaches to detect cis eQTL associations relevant
to QTs in LCL expression data are likely to require much larger
sample sizes than currently are thought necessary or available.
For many clinical phenotypes, comprehensive collections of
relevant human tissues are not commonly available. Although
previous studies have found a large number of eQTLs detected in
LCLs with large effect sizes which could also be detected in
primary tissues [21,22], the question is whether these LCL
expression profiles have any relevance to downstream clinical
traits. When we focussed on expression probes nominally
correlated with clinical QTs, we did not detect any large effect
eQTLs for these probes. Moreover, several studies have
highlighted cell type- or tissue specific genetic effects where others
found that a substantial numbers of eQTLs are shared across
tissues [12,20]. Hence, the detection of tissue-specific eQTLs with
smaller effect sizes is likely to be more important for QTs.
Although the proportion of expression variance explained by
the cis eQTL SNPs in our analyses appeared considerable, effect
sizes derived from small datasets are likely to be subject to the
‘winner’s curse’ [40]. In the overlap analysis of three HapMap
datasets, the proportion of expression variance explained by each
of 58 cis eQTL SNPs ranged from 17–46%, yet only two of these
signals were replicated in the Twin V2 analysis. Whilst we do not
currently know the spectrum of effect sizes for cis eQTL SNPs, and
assume that some of these will be of considerable magnitude, the
effect sizes of trans eQTLs are likely to be much smaller and similar
to those observed in complex traits. Moreover, the additional
multiple testing burden inherent to trans vs. cis analysis further
increases the likely sample sizes required.
It is perhaps not surprising that only one suggestive eQTL-QT
association among 44 QTs was observed in our study. In addition
to the size of the datasets employed for eQTL detection, we were
limited by the size of the twin sample with available LCLs
(N=299) to detect expression probe-QT correlations. Neverthe-
less, our results showed that the expression probe sets filtered at
each stage of analysis had progressively increasing heritability
levels, suggesting an enrichment of genetically relevant signals.
Further limitations arose because only 76% of the QT-correlated
probes were annotated across different expression platforms.
Testing SNPs tagging the eQTL SNPs for association with the
relevant QT in the twin cohort, we were able to follow up only 70–
75% of the eQTL SNPs due to the coverage of the available
genotyping data. This strategy will result in a loss of power
compared with testing the eQTL SNP itself, but has been
minimised by focussing on highly correlated tags (r
2.0.8, at least
80% power of eQTL SNP). An alternative approach to increase
power would be to perform imputation in the twins, although
current methodology [41] is not well calibrated for related
individuals. In addition, we were able to test only 56% of our
results for replication in large cohorts with GWA data and we
Figure 4. Sample sizes required to identify cis eQTL associations with 80% and 50% power at p,5
*10
27 and p,1
*10
23.
doi:10.1371/journal.pone.0022070.g004
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and phosphate levels, based on a cis eQTL signal, in an
independent dataset of 1,756 individuals. Given the sample sizes
required for the GWA detection of SNPs with QTs, the size of this
replication cohort may have been insufficient. Although some of
these problems may be resolved with the advent of large-scale
genotyping and gene expression profiling in large epidemiological
biobanks, they are nevertheless real issues inherent to currently
available datasets.
Because the physiology of specific cell types changes with
disease/QT, or the phenotype is manifested in specific tissues
exclusively, it appears logical that correlations between QT and
gene expression should be detectable in tissues relevant to the QT
in question. Although the number of nominally significant
correlations between QT and expression probes was more than
expected by chance in our study, it was lower than in previous
studies using gene expression profiling on liver or adipose tissue or
blood [12,14] suggesting that the effect sizes in LCLs might be
reduced compared to expression profiling in vivo tissues. Indeed, in
a recent study, 72% of the expression traits identified from adipose
tissue were significantly correlated with BMI whereas in blood this
was only 9%. More than 10% of the BMI variation was explained
by 16% of these expression traits whereas none of the correlated
expression traits in blood reached this level of correlation [12].
The extent to which eQTLs will be shared across tissues and cell
types is still unknown. We failed to confirm previously published
eQTL-QT associations derived from fresh lymphocytes, adipose
and liver tissue in the LCLs. The low percentage of overlap of
probe detection (66%) in LCLs suggests that some transcripts are
only expressed in specific tissues or have a better annotation on
other platforms. Indeed, in an eQTL analysis of three cell types
(LCLs, fibroblasts and T-cells), Dimas et al. (2009) detected cell
type-specific genetic effects, with 69%–80% of genetic variants
acting in a cell type-specific manner [20]. Emilsson et al. (2008)
showed little difference in the number of cis eQTLs mapped in
adipose tissue and blood with approximately 50% overlap
confirming that there is both common and tissue-specific genetic
control [12]. Highly significant cis eQTLs (unrelated to disease/
QT) have been found in LCLs [6–8,11] and some of these eQTLs
findings were replicated in lymphocytes [6,13]. Nica et al. (2010)
and Nicolae et al. (2010) observed a significant overrepresentation
of cis eQTLs in the LCLs of the HapMap individuals among
GWAS SNPs for immunity related traits as compared to random
SNPs [42,43]. Taken together, we speculate that the utility of
LCLs might be more powerful for traits with a more direct
immunological relevance.
The reproducibility of gene expression measurements has been
questioned, and lack of concordance attributed to the small sample
sizes and technical variability although this might also be a
reflection of the different annotation or statistical methods used
[24–26]. In our integrative approach, we found a few potential
QT-eQTL signals (a cis eQTL for phosphate and a trans eQTL for
height) which emerged only after three individually underpowered
eQTL HapMap datasets of HapMap founders were combined at a
nominal significance level. Notably, we also found suggestive
evidence for these eQTL associations in the 161 twins for which
we had genotypic and gene expression data available. This
highlights the fact that although the use of multiple gene
expression HapMap datasets can reduce the number of false
positive results caused by platform-specific technical artefacts
(technical replication), it cannot resolve low power to detect eQTL
signals due to small sample size (requiring biological replication)
and is hampered by the reduced number of the QT-correlated
probes (76%) that were annotated across platforms.
A few studies have adopted a different approach to detect QT-
related expression traits with small effect sizes by constructing of
co-expression networks. Specifically, they identified modules of co-
expressed probes and investigated the average correlation between
the expression probes in the module and obesity-related clinical
traits [12,14]. This is a potentially attractive and more powerful
approach, given that in theory it better reflects the complex nature
of gene expression networks, in which many expression traits will
not necessarily be causative of but mostly reactive to disease, and
in which each individual expression trait is likely only to have a
small effect [44]. Networks built on correlations between
expression traits, however, are likely to be noisy, as ultimately
any biases (experimental or otherwise) acting on expression levels
may cause artificial results if correlated with the clinical trait in
question. Although promising, it is at present unclear to what
extent the limitations that have hindered single expression trait
analyses impact on network or other types of multivariate analyses
of expression traits.
Although integrating genotype and gene expression with
multiple QTs in large datasets has the potential to improve our
understanding of common traits, our study found that approaches
using LCLs with currently available sample sizes are underpow-
ered. To detect associations between eQTLs and clinical
phenotypes, larger sample sizes are required and – if available -
datasets profiled on a tissue relevant to the clinical trait in question
should also be used. Such datasets will become available in the
near future, enabling a fuller exploration of the use of integrated
‘omics’ analyses in uncovering genetic origins of complex traits.
Methods
Study participants and QTs (Stage I & Stage III)
Study subjects comprised 6,533 female twins (age-range 19–81
years) from the St Thomas’ UK Adult Twin registry (www.
twinsuk.ac.uk). Twins were recruited from the general population
through national media campaigns in the UK and shown to be
comparable to age-matched population singletons in terms of
disease-related and lifestyle characteristics [45]. The study was
approved by St Thomas’ Hospital Research Ethics Committee
and all twins provided informed written consent.
Zygosity was determined with a standardized questionnaire and
confirmed through genotyping [46]. The study was approved by
St Thomas’ Hospital Research Ethics Committee and all twins
provided informed written consent. Administered questionnaires
provided information for an extensive range of demographic
variables and medical history. We selected 44 QTs including
blood pressure (systolic and diastolic blood pressure (first and
second measurements), sodium), BMD (lumbar spine, total hip,
femoral neck, and total forearm), bone (alkalinephosphatase,
calcium, vitamin D, phosphate and crp), and liver function
markers (albumin, bilirubin, total protein concentration and
gamma glutamyl transpeptidase activity), fat-related (triglycerides,
weight, BMI, total fat mass(g), total lean mass(g), central fat mass
(g), total fat mass (%), central fat mass (%), hip and waist
circumference, leptin, and adiponectin) and glycemic traits (fasting
insulin and glucose concentrations), electrolytes (bicarbonate, urea,
albumin corrected calcium, chloride, magnesium and potassium)
and lipids (cholesterol, HDL and LDL) and other (creatinine,
height and telomere length) (Text S1). The total sample of female
6,533 twins (1,428 monozygotic (MZ) and 1,829 dizygotic (DZ)
pairs, 12 singletons, one trio and a quadruple) was used for QT
heritability calculations. For the 44 QTs, phenotypic data was
available between 37%–99% of the twins. LCLs were available for
299 (101 MZ and 43 DZ pairs and 11 singletons) of the 6,533
Quantitative Trait-eQTL Associations from LCLs
PLoS ONE | www.plosone.org 11 July 2011 | Volume 6 | Issue 7 | e22070twins of which had between 43%–99% phenotypic data available
(Stage I). For the confirmation of QT-eQTL SNP associations,
genotypic data (Human Hap 300 k Duo chip, (Illumina, San
Diego, USA)) was available for 2,905 of the 6,533 female twins.
For 161 of the 2,905 female twins (86 families), LCL gene
expression and genotypic data was available.
Gene expression datasets
In Stage II, three datasets consisting of 60 CEU HapMap
founders were used: one publicly available dataset and two
generated for this study. The 299 twins were profiled using the
Illumina WG-6 Expression BeadChip V2; the 60 HapMap
individuals on the Illumina WG-6 Expression BeadChip V1 and
V2 (Table S3) (referred to as WTCHG V1 and V2 respectively). In
addition, we downloaded a publicly available gene expression
dataset [11] from the Gene Expression Omnibus website
(GSE6536) corresponding to the same HapMap individuals and
profiled on the Illumina WG-6 Expression Bead Chip V1. The
Illumina Human WG-6 V1 Sentrix BeadArray contains 47,296
probes representing 24,385 RefSeq annotated transcripts. The
Illumina Human-6 V2 Sentrix BeadArray contains 48,702 unique
probes representing 28,567 RefSeq annotated transcripts. LCLs
for the 299 twins were generated by the European Collection of
Cell Cultures, and cell pellets transported to the WTCHG. LCLs
from the 60 HapMap CEU individuals were purchased from
Coriell and cultured at WTCHG. The resultant data were parsed
with the software package BeadStudio (Illumina software) to
produce raw intensity values for all probes. Signal was checked for
quality using hybridisation and labelling controls internal to each
array and subtracted for background within the statistical scripting
environment, R v2.9.1 (http://cran.r-project.org/). Signal was
transformed and normalised using the variance stabilization
algorithm (vsn) and quantile normalization as implemented in
the vsn2 Bioconductor (http://www.bioconductor.org/) package
[47]. Transformed and normalised signal distributions for each
sample were investigated with unsupervised analysis and three
outliers NA11829, NA11839, NA12056 were removed from
WTCHG V1 and V2. We selected probes with an Illumina score
of .0.95 in at least six individuals (10%) and had no SNPs with
MAF.5% in their sequence, corresponding to 19,573 (twins),
20,200 (WTCHG V2) and 17,484 (WTCHG V1); 18,838 probes
overlapped between the twins and WTCHG V2. As detection
scores were not provided for the Stranger V1 dataset, the full
dataset was used [11]. Expression probes were sequence matched
to NCBI Build 36.1 (hg18) using the blastn algorithm to obtain a
physical position from which Ensembl transcript identifiers were
extracted and matched between Illumina’s expression profiling
arrays. (Text S1, Table S3 and S4).
Statistical analysis
Correlations between QTs and gene expression probes
(Stage I). For QTs measured at multiple time points, the
timepoint closest to extraction of the lymphocytes was used.
Outlying values for each QT were identified and removed on basis
of the distribution of the larger twin cohort. Skewed distributions
of QTs were logarithmically or square root transformed to
normalise distributions before analyses. To investigate the
correlation structure of the QTs, PCA was performed using the
NIPALS algorithm and Pearson correlations among the 44 QTs
were calculated.
Phenotype correlations between 19,573 normalised gene
expression levels and 44 QTs were computed using mixed models
(lmer) implemented in the R package lme4. For logistical reasons
beyond our control, twin pairs were always assessed and measured
together. Mixed models were adjusted for correlation of measure-
ments due to relatedness of the twins.
Possible confounders were identified by comparing the log
likelihood of the mixed model with and without the possible
confounder for each phenotype. In the mixed model, we included
age, number of flask days, RNA Integrity Number as fixed effects
and twin relationship as random effect.
eQTL analyses in the HapMap and Twin datasets
(Stage II). Nominally significant correlated expression probes
(P,10
23) were tested for association in cis or trans with 2.2 million
autosomal SNPs (r
2,1.0; MAF .0.05, HapMap release 22, NCBI
build 36) in three datasets of CEU HapMap founders or with
296,308 SNPs (MAF.0.05) in 86 unrelated twins that were
profiled and genotyped from Stage I. Probes selected in Stage I
(939 probes) that were not mapped to an autosomal genomic
location in build 36 or mapped to multiple locations resulting in
718 probes used in the WTCHG V2 analysis or Twin V2 analysis.
We were able to annotate 546 of the 718 V2 probes to 1,050 V1
probes and this set was analysed in the overlap analysis consisting
of three HapMap datasets. For each of the selected expression
probes and for each SNP, an one degree of freedom test (Wald
test) was fitted using PLINK [48]. The genotypes were coded as 0,
1 and 2 and these allele counts were tested for an additive
genotypic effect with the normalised gene expression values in
each of the three HapMap datasets separately or Twin V2 dataset.
Nominal significance thresholds of p,1*10
23 in all three
HapMap datasets or p,5*10
27 (a commonly used GWA
threshold previously employed by the Wellcome Trust Case
Control Consortium [3]) in the WTCHG V2 or Twin V2 dataset
were applied. Fixed-effects meta-analyses on WTCHG V2 and
Twin V2 for 229 eQTL associations were performed using
estimates of the allelic effect size and standard error [31]. eQTL
associations from the overlap analyses and meta-analyses were
checked for different directional genotypic effects. Associations in
cis were defined as a SNP-probe association where the distance
from probe genomic midpoint to SNP genomic location was less
than or equal to 1 Mb [11]. All other associations were defined as
associations in trans [11]. Given the redundancy of the V1 probes
compared to the V2 probes and the correlation between
expression probes, we used Illumina V2 probe identifiers as an
annotation reference.
SNP-QT associations in the twin cohort (Stage III). For
the TwinsUK cohort, 2,167 samples were successfully genotyped
with the Illumina HumanHap 300 k Duo Beadchip (Illumina, San
Diego, USA). For the second individual of a MZ pair, genotypes
were copied from the other genotyped MZ individual of the pair.
After applying strict quality control filters we retained 296,308
autosomal SNPs with a MAF.0.05 and 2,905 female twins (Text
S1). From the eQTL analysis in Stage II, we selected 1,989 eQTL
SNPs from the overlap analysis and 1,932 eQTL SNPs from the
WTCHG V2 analysis. Pairwise r
2 values and MAF from the
International HapMap Project [30] were used to assess which
SNPs were in LD (r
2.0.8) with the eQTL SNPs and to compare
MAF distributions. From the SNPs in LD with the eQTL SNPs,
535 SNPs for the overlap analysis and 451 SNPs for the WTCHG
V2 analysis were present on the Illumina HumanHap 300 k Duo
Beadchip, successfully genotyped in the twin cohort and had
passed QC. These SNP sets, which tagged (r
2.0.8) 1,482/1,989 of
the eQTL SNPs from the overlap analysis and 1,357/1,932 from
the WTCHG V2 analysis, were tested for association with 37 QTs
and 41 QTs, respectively. In addition, 242 SNPs from the Twin
V2 and 101 SNPs from the meta-analysis were tested for
association with 38 QTs and 36 QTs, respectively. Genotyped
eQTL SNPs or their proxies were tested for association with the
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adjusted for family relationship and zygosity. We tested the
additive genotypic effect of the SNP, coded as 0, 1, and 2 with the
transformed QT using the lmer function in the lme4 R package
and assessed significance by applying a FDR [33]. Adjustment for
age did not modify the association between the SNPs and the
clinical phenotypes (except for telomere length, data not shown).
SNP-QT associations (p,0.01) were checked for outlying values in
gene expression distributions. For the remaining 16 SNP-QT
associations with p,0.01, eQTL associations were tested in the
full set of 86 twin families (161 individuals), using a linear mixed
model adjusted for family relationship and zygosity.
Follow-up of SNP-QT associations in independent cohorts
(Stage IV). In order to confirm the nine SNP-QT associations in
independent cohorts, we obtained results of relevant meta-analyses
conducted by five different consortia. To confirm the height
association, three SNPs (rs1482455, rs9342097, rs9353441) were
tested in 5,828 European females from three GWA studies: the
British 1958 Birth Cohort, the Rotterdam Study and EPIC Norfolk
study. Meta-analysis statistics were obtained using a weighted z-
statistics [49]. For the three crp associations, five SNPs were
examined for association in a subcohort (Genmets) of the
Health2000 population cohort consisting of 1,097 European
women with metabolic syndrome and matched healthy controls
usingan additive modeladjustedforcase-controlstatusandage [34].
SNP (rs2266917) was tested for association with triglyceride levels in
the ENGAGE cohort datasets comprising 16,129 individuals from
14 GWA studies (excluding TwinsUK individuals) using a fixed-
effects meta-analysis with reciprocal weighting [35]. For the
associations with diastolic blood pressure, three SNPs (rs200969,
rs149900 and rs12150466) were examined in 26,644 women of the
Global BPgen consortium blood comprising 17 GWAS studies using
inverse variance weighting [36]. In the population-based KORA
study comprising two follow-up populations of 1,756 (F3:829,
F4:927) women of European descent, we examined two SNPs,
rs10511409 and rs7647266, for association with phosphate levels
using an inverse variance meta-analysis [37].
Gene set enrichment, heritability estimates and power
calculations
We used DAVID to conduct GO term enrichment analysis
[32]. A Fisher Exact test was used to assess significance and a FDR
was used to adjust for multiple testing [33]. Heritabilities were
calculated using a structural equation modelling framework in Mx
[50]. Sample sizes needed to detect eQTLs with effects varying
between 0.01 and 0.4 of QTL variance explained, assuming a
significance threshold a of 5*10
27 or 1.0*10
23, and 50% or 80%
power, were conducted using the Genetic Power Calculator [39].
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